225 related articles for article (PubMed ID: 10085043)
1. Vaccination and protection of pigs against pleuropneumonia with a vaccine strain of Actinobacillus pleuropneumoniae produced by site-specific mutagenesis of the ApxII operon.
Prideaux CT; Lenghaus C; Krywult J; Hodgson AL
Infect Immun; 1999 Apr; 67(4):1962-6. PubMed ID: 10085043
[TBL] [Abstract][Full Text] [Related]
2. Characterization and immunogenicity of an apxIA mutant of Actinobacillus pleuropneumoniae.
Xu F; Chen X; Shi A; Yang B; Wang J; Li Y; Guo X; Blackall PJ; Yang H
Vet Microbiol; 2006 Dec; 118(3-4):230-9. PubMed ID: 16930871
[TBL] [Abstract][Full Text] [Related]
3. [Construction and immunogenicity of an attenuated mutant of Actinobacillus pleuropneumoniae by insertional inactivation of apxIC].
Xu FZ; Shi AH; Chen XL; Yang B; Wang JL
Wei Sheng Wu Xue Bao; 2007 Oct; 47(5):923-7. PubMed ID: 18062275
[TBL] [Abstract][Full Text] [Related]
4. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs.
Shin MK; Kang ML; Jung MH; Cha SB; Lee WJ; Kim JM; Kim DH; Yoo HS
Vet Immunol Immunopathol; 2013 Jan; 151(1-2):132-9. PubMed ID: 23206402
[TBL] [Abstract][Full Text] [Related]
5. Construction and immunogencity of a DeltaapxIC/DeltaapxIIC double mutant of Actinobacillus pleuropneumoniae serovar 1.
Lin L; Bei W; Sha Y; Liu J; Guo Y; Liu W; Tu S; He Q; Chen H
FEMS Microbiol Lett; 2007 Sep; 274(1):55-62. PubMed ID: 17608699
[TBL] [Abstract][Full Text] [Related]
6. Nasal immunization with major epitope-containing ApxIIA toxin fragment induces protective immunity against challenge infection with Actinobacillus pleuropneumoniae in a murine model.
Seo KW; Kim SH; Park J; Son Y; Yoo HS; Lee KY; Jang YS
Vet Immunol Immunopathol; 2013 Jan; 151(1-2):102-12. PubMed ID: 23200821
[TBL] [Abstract][Full Text] [Related]
7. Molecular investigation of the role of ApxI and ApxII in the virulence of Actinobacillus pleuropneumoniae serotype 5.
Reimer D; Frey J; Jansen R; Veit HP; Inzana TJ
Microb Pathog; 1995 Mar; 18(3):197-209. PubMed ID: 7565014
[TBL] [Abstract][Full Text] [Related]
8. New trends in innovative vaccine development against Actinobacillus pleuropneumoniae.
Loera-Muro A; Angulo C
Vet Microbiol; 2018 Apr; 217():66-75. PubMed ID: 29615259
[TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of a live, attenuated apxIICA inactivation mutant of Actinobacillus pleuropneumoniae lacking a drug resistance marker.
Bei W; He Q; Yan L; Fang L; Tan Y; Xiao S; Zhou R; Jin M; Guo A; Lv J; Huang H; Chen H
FEMS Microbiol Lett; 2005 Feb; 243(1):21-7. PubMed ID: 15667996
[TBL] [Abstract][Full Text] [Related]
10. Potential use an Actinobacillus pleuropneumoniae double mutant strain DeltaapxIICDeltaapxIVA as live vaccine that allows serological differentiation between vaccinated and infected animals.
Liu J; Chen X; Lin L; Tan C; Chen Y; Guo Y; Jin M; Guo A; Bei W; Chen H
Vaccine; 2007 Nov; 25(44):7696-705. PubMed ID: 17767980
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of the role of antibodies to Actinobacillus pleuropneumoniae serovar 1 and 15 in the protection provided by sub-unit and live streptomycin-dependent pleuropneumonia vaccines.
Tumamao JQ; Bowles RE; van den Bosch H; Klaasen HL; Fenwick BW; Blackall PJ
Aust Vet J; 2004 Dec; 82(12):773-80. PubMed ID: 15648941
[TBL] [Abstract][Full Text] [Related]
12. [Construction and characterization of Actinobacillus pleuropneumoniae serovar 7 live attenuated vaccine strain co-expressing ApxIA].
Liu J; Chen Y; Hu L; Bei W; Chen H
Sheng Wu Gong Cheng Xue Bao; 2010 Mar; 26(3):305-10. PubMed ID: 20518341
[TBL] [Abstract][Full Text] [Related]
13. Protection of mice against challenge with homologous and heterologous serovars of Actinobacillus pleuropneumoniae after live vaccination.
Prideaux CT; Pierce L; Krywult J; Hodgson AL
Curr Microbiol; 1998 Nov; 37(5):324-32. PubMed ID: 9767712
[TBL] [Abstract][Full Text] [Related]
14. Influences of ORF1 on the virulence and immunogenicity of Actinobacillus pleuropneumoniae.
Yuan F; Liu J; Guo Y; Tan C; Fu S; Zhao J; Chen H; Bei W
Curr Microbiol; 2011 Dec; 63(6):574-80. PubMed ID: 21964939
[TBL] [Abstract][Full Text] [Related]
15. Interference of outer membrane protein PalA with protective immunity against Actinobacillus pleuropneumoniae infections in vaccinated pigs.
van den Bosch H; Frey J
Vaccine; 2003 Sep; 21(25-26):3601-7. PubMed ID: 12922088
[TBL] [Abstract][Full Text] [Related]
16. Galactose-1-phosphate uridyltransferase (GalT), an in vivo-induced antigen of Actinobacillus pleuropneumoniae serovar 5b strain L20, provided immunoprotection against serovar 1 strain MS71.
Zhang F; Zhao Q; Quan K; Zhu Z; Yang Y; Wen X; Chang YF; Huang X; Wu R; Wen Y; Yan Q; Huang Y; Ma X; Han X; Cao S
PLoS One; 2018; 13(6):e0198207. PubMed ID: 29856812
[TBL] [Abstract][Full Text] [Related]
17. Both ApxI and ApxII of Actinobacillus pleuropneumoniae serotype 1 are necessary for full virulence.
Boekema BK; Kamp EM; Smits MA; Smith HE; Stockhofe-Zurwieden N
Vet Microbiol; 2004 May; 100(1-2):17-23. PubMed ID: 15135509
[TBL] [Abstract][Full Text] [Related]
18. Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
Maas A; Meens J; Baltes N; Hennig-Pauka I; Gerlach GF
Vaccine; 2006 Nov; 24(49-50):7226-37. PubMed ID: 17027123
[TBL] [Abstract][Full Text] [Related]
19. Nasal immunization with M cell-targeting ligand-conjugated ApxIIA toxin fragment induces protective immunity against Actinobacillus pleuropneumoniae infection in a murine model.
Park J; Seo KW; Kim SH; Lee HY; Kim B; Lim CW; Kim JH; Yoo HS; Jang YS
Vet Microbiol; 2015 May; 177(1-2):142-53. PubMed ID: 25818577
[TBL] [Abstract][Full Text] [Related]
20. Protective efficacy of an affinity-purified hemolysin vaccine against experimental swine pleuropneumonia.
Haga Y; Ogino S; Ohashi S; Ajito T; Hashimoto K; Sawada T
J Vet Med Sci; 1997 Feb; 59(2):115-20. PubMed ID: 9070983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
